N
FOLD

Natixis’s Amicus Therapeutics FOLD Stock Holding History

Natixis’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-47,250
Closed -$670K – 1082
2023
Q4 		$670K Buy
47,250
+7,600
+19% +$86.3K ﹤0.01% 583
2023
Q3 		$482K Buy
39,650
+39,600
+79,200% +$511K ﹤0.01% 612
2023
Q2 		$628 Buy
+50
New +$593 ﹤0.01% 975
2021
Q2 		– Sell
-18,186
Closed -$180K – 893
2021
Q1 		$180K Sell
18,186
-97,484
-84% -$1.51M ﹤0.01% 1031
2020
Q4 		$2.67M Buy
+115,670
New +$2.37M 0.01% 627
2019
Q1 		– Sell
-37,872
Closed -$363K – 818
2018
Q4 		$363K Buy
37,872
+2,472
+7% +$27.2K ﹤0.01% 606
2018
Q3 		$428K Sell
35,400
-41
-0.1% -$573 ﹤0.01% 649
2018
Q2 		$554K Buy
35,441
+15,839
+81% +$239K ﹤0.01% 683
2018
Q1 		$295K Sell
19,602
-17,309
-47% -$263K ﹤0.01% 750
2017
Q4 		$531K Buy
+36,911
New +$507K ﹤0.01% 593

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Natixis's FOLD Position: Q1 2024 in Review

Natixis sold out of Amicus Therapeutics (FOLD) in Q1 2024, closing a stake of 47,250 shares — an estimated $670K sold.

Natixis first reported a position in FOLD in Q4 2017 and held it in 10 quarters. The position peaked at $2.67M in Q4 2020. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

  • Natixis reported no remaining Amicus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 47,250 Amicus Therapeutics shares in Q1 2024, an estimated $670K.
  • Natixis first reported a position in Amicus Therapeutics in Q4 2017 and held it in 10 quarters.
  • Natixis's Amicus Therapeutics position peaked at $2.67M in Q4 2020.
  • 254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.